-
In this study, 73 patients (19 males, 26.03%; 54 females, 73.97%) were enrolled, consisiting of 36 with Chinese herbal medicine (group A), 6 with cardiovascular drugs (group B), 10 with NSAIDs (group C), 7 with anti-infective drugs (group D), and 14 with other drugs (group E). The basic demographic characteristics and clinical parameters (sex, age, ALT level, TBil level, AST level, DBIL level, GGT level, Total bile acids (TBA) level, ALP level and ALB level) of these patients are discribed in Table 1. The age among five groups was statistically different (P = 0.032; H = 10.567), and the age in patients with Chinese herbal medicine (P = 0.032), NSAIDs group (P = 0.002), and anti-infective drug group (P = 0.008) was dramatically lower than that in patients with cardiovascular drug. The ALT levels and AST levels in patients with Chinese herbal medicine (ALT: P = 0.033, Z = −2.130; AST: P = 0.007, Z = −2.663) were markedly lower than those in patients with NSAIDs. The TBiL and DBiL levels in patients with Chinese herbal medicine (TBIL: P = 0.002, Z = −3.131; DBIL: P = 0.001, Z = −3.143) and cardiovascular medicine (TBIL: P = 0.003, Z = −2.820; DBIL: P = 0.005, Z = −2.712) were markedly lower than those in patients with NSAIDs. The ALP and TBA levels in patients with Chinese herbal medicine (ALP: P = 0.005, Z = −2.770; TBA: P = 0.010, Z = −2.539) were markedly lower than those in patients with NSAIDs. There was no significant statistical differences in GGT and ALB among five groups. IL-6 (P < 0.001; H = 23.937) and TNF-α (P < 0.001; H = 24.417) among five groups were statistically different, and the levels of IL-6 and TNF-α in patients with Chinese herbal medicine (IL-6: P < 0.001, Z = −3.937; TNF-α: P < 0.001, Z = −4.407) and cardiovascular medicine (IL-6: P = 0.020, Z = −2.321; TNF-α: P = 0.001, Z = −3.497) were markedly lower than those in patients with NSAIDs.
Cytokines Group A
(n = 36)Group B
(n = 6)Group C
(n = 10)Group D
(n = 7)Group E
(n = 14)P1 (group A vs. group B) P2 (group A vs. group C) P3 (group A vs. group D) P4 (group B vs. group C) P5 (group B vs. group D) P6 (group C vs. group D) P Age (years) 50.00
(38.25, 57.00)61.00
(51.50, 67.50)46.00
(33.50, 54.25)44.00
(20.00, 49.00)39.00
(27.00, 48.00)Z = −2.141;
P = 0.032Z = −0.960;
P = 0.350Z = −2.009;
P = 0.045Z = −2.288;
P = 0.002Z = −2.571;
P = 0.008Z = −0.980;
P = 0.364H = 10.567;
P = 0.032Male (%) 6/36
(16.67)1/6
(16.67)2/10
(20.00)5/7
(71.43)5/14
(35.71)/ χ2 = 1.061;
P = 0.808χ2 = 9.232;
P = 0.000χ2 = 1.027;
P = 0.869χ2 = 3.899;
P = 0.078χ2 = 4.651;
P = 0.031χ2 = 8.980;
P = 0.034ALT
(U/L)277.50
(102.50, 604.00)94.00
(68.18, 585.90)537.50
(373.75, 921.25)453.00
(169.00, 1189.30)173.00
(139.70, 620.00)Z = −0.935;
P = 0.350Z = −2.130;
P = 0.033Z = −0.773;
P = 0.448Z = −1.844;
P = 0.073Z = −1.429;
P = 0.181Z = −0.488;
P = 0.669H = 4.921;
P = 0.296AST
(U/L)182.50
(79.35,327.00)130.35
(49.78, 468.18)592.00
(273.75,1002.00)252.00
(132.00, 312.00)167.00
(80.00,225.00)Z = −0.539;
P = 0.611Z = −2.663;
P = 0.007Z = −0.504;
P=0.636Z = −1.735;
P = 0.093Z = −0.571;
P = 0.628Z = −1.561;
P = 0.133H = 6.076;
P = 0.194TBiL (μmol/L) 19.00
(13.93,54.25)23.00
(8.48,31.78)96.00
(42.25,207.00)29.00
(25.30,63.00)18.00
(11.00,62.00)Z = −0.611;
P = 0.562Z = −3.131;
P = 0.002Z = −1.48;
P = 0.146Z = −2.820;
P = 0.003Z = −1.574;
P = 0.138Z = −1.465;
P = 0.161H = 107.616;
P = 0.001DBiL (μmol/L) 8.85
(5.08, 40.25)11.45
(2.63, 20.25)66
(25.25, 138.00)16.40
(12.00,43.00)5.10
(3.60, 48.00)Z = −0.413;
P = 0.687Z = −3.143;
P = 0.001Z = −1.629;
P = 0.104Z = −2.712;
P = 0.005Z = −1.429;
P = 0.181Z = −1.466;
P = 0.161H = 11.017;
P = 0.026GGT (U/L) 113.25
(58.60, 274.75)214.00
(157.25, 540.48)170.00
(104.50, 230.25)178.00
(147.00, 212.00)141.00
(93.00,271.00)Z = −1.833;
P = 0.069Z = −0.812;
P = 0.423Z = −1.119;
P = 0.277Z = −1.193;
P = 0.263Z = −1.143;
P = 0.295Z = −0.293;
P = 0.813H = 4.223;
P = 0.377ALP
(U/L)103.00
(85.00, 162.00)158.00
(101.03,282.63)171.00
(136.75,205.50)173.00
(88.80, 953.00)127.00
(94.40,196.00)Z = −1.474;
P = 0.149Z = −2.770;
P = 0.005Z = −1.513;
P = 0.137Z = −0.108;
P = 0.958Z = −0.143;
P = 0.945Z = −0.098;
P = 0.962H = 9.249;
P = 0.055TBA
(umol/L)16.00
(7.10,75.80)35.10
(10.33, 139.00)165.00
(19.75, 204.50)109.60
(8.00,202.00)16.00
(6.80,66.00)Z = −0.719;
P = 0.482Z = −2.539;
P = 0.010Z = −0.911;
P = 0.370Z = −1.519;
P = 0.147Z = −0.571;
P = 0.628Z = −0.781;
P = 0.475H = 6.694;
P = 0.153ALB
(g/L)38.00
(35.05, 41.65)36.00
(33.98, 40.73)36.50
(30.20,40.00)40.00
(38.00, 45.30)39.00
(38.00,44.00)Z = −0.612;
P = 0.562Z = −1.242;
P = 0.219Z = −1.238;
P = 0.223Z = −0.489;
P = 0.635Z = −1.363;
P = 0.181Z = −1.625;
P = 0.109H = 7.516;
P = 0.111IFN-α2 (pg/mL) 85.20
(64.27, 169.06)26.76
(13.49, 89.13)76.08
(32.13, 133.99)59.16
(48.38, 119.63)65.75
(23.09, 125.92)Z = 1.993;
P = 0.053Z = 0.862;
P = 0.394Z = 1.015;
P = 0.316Z = −1.309;
P = 0.212Z = −1.134;
P = 0.281Z = 0.250;
P = 0.806H = 6.919;
P = 0.140IFN-γ (pg/mL) 12.96
(8.15, 35.72)4.74
(3.10, 13.71)12.59
(6.71, 20.70)11.90
(8.15, 27.13)9.86
(5.64, 23.93)Z = 1.576;
P = 0.123Z = 0.928;
P = 0.358Z = 0.959;
P = 0.343Z = −1.246;
P = 0.233Z = −1.356;
P = 0.202Z = 0.227;
P = 0.823H = 5.719;
P = 0.221IL-10 (pg/mL) 19.57
(5.56, 46.05)1.86
(1.10, 11.50)11.27
(3.50, 34.59)25.80
(4.94, 34.02)7.16
(1.97, 21.56)Z = 0.728;
P = 0.471Z = 0.747;
P = 0.459Z = 0.522;
P = 0.604Z = −1.700;
P = 0.111Z = −1.770;
P = 0.104Z = −0.730;
P = 0.476H = 11.340;
P = 0.023IL-17A (pg/mL) 8.15
(4.12, 19.58)2.83
(1.55, 9.87)6.49
(3.11, 14.05)9.17
(4.27, 12,94)6.19
(2.56, 12.88)Z = 1.526;
P = 0.135Z = 0.952;
P = 0.346Z = 0.791;
P = 0.433Z = −0.896;
P = 0.386Z = −1.044;
P = 0.319Z = −0.043;
P = 0.966H = 5.400;
P = 0.249IL-2 (pg/mL) 1.74
(1.45, 2.80)0.96
(0.81, 1.72)1.84
(1.21, 2.36)1.49
(1.33, 2.00)1.46
(1.15, 2.43)Z = 2.004;
P = 0.052Z = −0.402;
P = 0.690Z = 0.827;
P = 0.413Z = −1.488;
P = 0.159Z = −1.446;
P = 0.176Z = 0.765;
P = 0.456H = 6.531;
P = 0.163IL-6 (pg/mL) 0.34
(0.21, 0.53)0.45
(0.21, 1.09)1.56
(1.02, 2.45)0.33
(0.15, 0.45)0.14
(0.12, 0.38)Z = −0.474;
P = 0.636Z = −3.973;
P = 0.000Z = −0.458;
P = 0.647Z = −2.321;
P = 0.020Z = −0.715;
P = 0.474Z = 3.239;
P = 0.001H = 23.937;
P = 0.000TNF-α (pg/mL) 30.58
(20.07, 42.66)23.35
(16.20, 46.01)93.06
(78.01, 100.32)23.93
(19.45, 33.29)25.64
(20.06, 44.86)Z = 0.523;
P = 0.601Z = −4.407;
P = 0.000Z = 0.770;
P = 0.441Z = −3.497;
P = 0.001Z = −0.157;
P = 0.875Z = 3.845;
P = 0.000H = 24.417;
P = 0.000TGF-β1 (pg/mL) 7230.50
(3774.25,
24424.75)4568.00
(1973.50,
8217.750)6978.50
(3209.50,
18378.25)8881.00
(2036.00,
16644.00)6198.50
(2571.00,
20192.00)Z = 1.380;
P = 0.175Z = 0.653;
P = 0.517Z = 0.630;
P = 0.532Z = −1.303;
P = 0.214Z = −1.270;
P = 0.230Z = 0.095;
P = 0.925H = 2.344;
P = 0.673Note. Data with non-normal distribution is described by median and quartile counts (meadian, Q1, Q3); group A: chinese herbal medicine group; group B: cardiovascular drugs group; group C: NSAIDs group; group D: anti infective drugs group; and group E: other drugs group. P1: The contrast between group A and group B; P2: The contrast between group A and group C; P3: The contrast between group A and group D; P4: The contrast between group B and group C; P5: The contrast between group B and group D; P6: The contrast between group C and group D; P: Comparison among five groups. P < 0.05 was regarded as statistical significance. NSAIDs: non-steroidal anti-inflammatory drugs; ALT: Alanine aminotransferase, AST: aspartate aminotransferase, TBIL: Total bilirubin, DBIL: Direct bilirubin, GGT: glutamine transferase, ALP: alkaline phosphatase, TBA: Total bile acid, ALB: albumin, IFN-α2: interferon-alpha2, IFN-γ: interferon-gamma, IL-10: Interleukin-10, IL-17A: Interleukin-17A, IL-2: Interleukin-2, IL-6: Interleukin-6, TNF-α: tumor necrosis factor alpha, TGF-β1: transforming growth factor-beta1. Table 1. Comparison of cytokine levels and clinical indicators among five groups
-
The Correlation of Clinical Indicators and Cytokine Levels In Chinese Herbal Medicine Group In patients treated with Chinese herbal medicine, data showed that TBIL was positively correlated with IL-17A (r = 0.355, P = 0.034), but our results indicated that there were no significant correlations between other cytokines and clinincal indexes in Table 2.
Cytokines ALT (U/L) AST (U/L) TBiL (μmol/L) DBiL (μmol/L) GGT (U/L) ALP (U/L) TBA (μmol/L) ALB (g/L) IFN-α2 (pg/mL) r = 0.070;
P = 0.549r = 0.013;
P = 0.913r = −0.169;
P = 0.152r = −0.139;
P = 0.236r = 0.081;
P = 0.487r = 0.005;
P = 0.967r = −0.038;
P = 0.744r = −0.161;
P = 0.176IFN-γ (pg/mL) r = −0.062;
P = 0.595r = -0.053;
P = 0.653r = −0.197;
P = 0.096r = −0.119;
P = 0.313r = 0.058;
P = 0.623r = −0.029;
P = 0.806r = −0.021;
P = 0.859r = −0.046;
P = 0.702IL-10 (pg/mL) r = −0.139;
P = 0.236r = −0.065;
P = 0.576r = −0.199;
P = 0.091r = −0.105;
P = 0.368r = −0.006;
P = 0.957r = −0.013;
P = 0.913r = −0.014;
P = 0.902r = −0.075;
P = 0.529IL-17A (pg/mL) r = 0.133;
P = 0.257r = −0.111;
P = 0.346r = 0.355;
P = 0.034*r = −0.203;
P = 0.086r = 0.058;
P = 0.623r = −0.045;
P = 0.702r = −0.014;
P = 0.902r = −0.085;
P = 0.474IL-2 (pg/mL) r = −0.099;
P = 0.398r = −0.131;
P = 0.264r = −0.208;
P = 0.078r = −0.187;
P = 0.111r = −0.024;
P = 0.838r = −0.059;
P = 0.614r = −0.042;
P = 0.723r = −0.023;
P = 0.848IL-6 (pg/mL) r = −0.014;
P = 0.902r = 0.075;
P = 0.522r = −0.083;
P = 0.478r = 0.006;
P = 0.957r = 0.096;
P = 0.414r = 0.038;
P = 0.744r = 0.104;
P = 0.376r = 0.020;
P = 0.870TNF-α2 (pg/mL) r = 0.026;
P = 0.827r = 0.051;
P = 0.663r = −0.155;
P = 0.190r = −0.130;
P = 0.269r = 0.014;
P = 0.902r = 0.046;
P = 0.692r = −0.013;
P = 0.913r = −0.085;
P = 0.477TGF-β1 (pg/mL) r = −0.107;
P = 0.361r = −0.094;
P = 0.421r = −0.039;
P = 0.743r = −0.006;
P = 0.957r = 0.083;
P = 0.479r = 0.131;
P = 0.264r = 0.080;
P = 0.496r = −0.229;
P = 0.054Note. ALT: Alanine aminotransferase, AST: aspartate aminotransferase, TBiL: Total bilirubin, DBiL: Direct bilirubin, GGT: glutamine transferase, ALP: alkaline phosphatase, TBA: Total bile acid, ALB: albumin, IFN-α2: interferon-alpha2, IFN-γ: interferon-gamma, IL-10: Interleukin-10, IL-17A: Interleukin-17A, IL-2: Interleukin-2, IL-6: Interleukin-6, TNF-α: tumor necrosis factor alpha, TGF-β1: transforming growth factor-beta1. *: P < 0.05. Table 2. The correlation between clinical indicators and cytokines in chinese herbal medicine group
The Correlation of Clinical Indicators and Cytokine Levels In Cardiovascular Medicine Group In patients with cardiovascular medicine, our results indicated that there were no significant correlations between other cytokines and clinincal indexes in Table 3.
Cytokines ALT (U/L) AST (U/L) TBiL (μmol/L) DBiL (μmol/L) GGT (U/L) ALP (U/L) TBA (μmol/L) ALB (g/L) IFN-α2 (pg/mL) r = −0.086;
P = 0.872r = −0.029;
P = 0.957r = 0.600;
P = 0.208r = 0.468;
P = 0.329r = −0.314;
P = 0.544r = 0.486;
P = 0.329r = 0.829;
P = 0.051r = −0.429;
P = 0.397IFN-γ (pg/mL) r = −0.371;
P = 0.468r = −0.543;
P = 0.266r = 0.314;
P = 0.544r = 0.086;
P = 0.872r = −0.257;
P = 0.623r = 0.086;
P = 0.872r = 0.314;
P = 0.544r = −0.029;
P = 0.957IL-10 (pg/mL) r = −0.543;
P = 0.266r = −0.371;
P = 0.468r = 0.486;
P = 0.329r = 0.257;
P = 0.623r = 0.257;
P = 0.623r = 0.600;
P = 0.208r = 0.486;
P = 0.329r = 0.143;
P = 0.787IL-17A (pg/mL) r = −0.058;
P = 0.913r = −0.116;
P = 0.827r = 0.638;
P = 0.173r = 0.493;
P = 0.321r = −0.377;
P = 0.461r = 0.232;
P = 0.658r = 0.725;
P = 0.103r = −0.464;
P = 0.354IL-2 (pg/mL) r = −0.486;
P = 0.329r = −0.600;
P = 0.208r = −0.086;
P = 0.872r = −0.257;
P = 0.623r = −0.429;
P = 0.397r = 0.486;
P = 0.329r = 0.371;
P = 0.468r = 0.143;
P = 0.787IL-6 (pg/mL) r = −0.828;
P = 0.054r = −0.812;
P = 0.051r = −0.406;
P = 0.425r = −0.638;
P = 0.173r = 0.754;
P = 0.084r = 0.493;
P = 0.321r = −0.580;
P = 0.228r = 0.828;
P = 0.054TNF-α2 (pg/mL) r = −0.657;
P = 0.156r = −0.429;
P = 0.397r = 0.314;
P = 0.544r = 0.086;
P = 0.872r = 0.486;
P = 0.329r = 0.714;
P = 0.111r = 0.257;
P = 0.623r = 0.314;
P = 0.544TGF-β1 (pg/mL) r = −0.714;
P = 0.111r = −0.600;
P = 0.208r = 0.371;
P = 0.468r = 0.086;
P = 0.872r = 0.371;
P = 0.468r = 0.486;
P = 0.329r = 0.257;
P = 0.623r = 0.371;
P = 0.468Note. ALT: Alanine aminotransferase, AST: aspartate aminotransferase, TBiL: Total bilirubin, DBiL: Direct bilirubin, GGT: glutamine transferase, ALP: alkaline phosphatase, TBA: Total bile acid, ALB: albumin, IFN-α2: interferon-alpha2, IFN-γ: interferon-gamma, IL-10: Interleukin-10, IL-17A: Interleukin-17A, IL-2: Interleukin-2, IL-6: Interleukin-6, TNF-α: tumor necrosis factor alpha, TGF-β1: transforming growth factor-beta1. NSAIDs: non-steroidal anti-inflammatory drugs. Table 3. The correlation between clinical indicators and cytokines in cardiovascular drugs group
The Correlation of Clinical Indicators and Cytokine Levels In NSAIDs Group In patients with NSAIDs, IL-6 level and ALT level presented a positive correlation (r = 0.697, P = 0.025), meanwhile, IL-6 was positively correlated to AST (r = 0.721, P = 0.019) in Figure 1. However, our results indicated that there were no significant correlations between other cytokines and clinical indexes.
Figure 1. The correlation between clinical indicators and cytokines in NSAIDs group. NSAIDs, non-steroidal anti-inflammatory drugs; ALT, Alanine aminotransferase, AST, aspartate aminotransferase; IL-6, Interleukin-6
The Correlation Of Cytokine Levels And Clinical Indicators In Anti-infective Drugs Group And Other Drugs Group In patients who received anti-infective drugs or other drugs, we didn’t find that cytokines were correlated with clinical indexes in Table 4 and Table 5.
Cytokines ALT (U/L) AST (U/L) TBiL (μmol/L) DBiL (μmol/L) GGT (U/L) ALP (U/L) TBA (μmol/L) ALB (g/L) IFN-α2 (pg/mL) r = −0.036;
P = 0.939r = −0.143;
P = 0.760r = −0.694;
P = 0.115r = −0.714;
P = 0.071r = −0.464;
P = 0.294r = −0.821;
P = 0.021r = −0.571;
P = 0.180r = 0.805;
P = 0.051IFN-γ (pg/mL) r = −0.396;
P = 0.379r = −0.378;
P = 0.403r = 0.173;
P = 0.711r = 0.108;
P = 0.818r = −0.270;
P = 0.558r = −0.523;
P = 0.229r = 0.162;
P = 0.728r = 0.569;
P = 0.183IL-10 (pg/mL) r = −0.143;
P = 0.760r = 0.179;
P = 0.702r = 0.613;
P = 0.144r = 0.536;
P = 0.215r = −0.214;
P = 0.645r = −0.071;
P = 0.879r = 0.500;
P = 0.253r = 0.018;
P = 0.969IL-17A (pg/mL) r = −0.468;
P = 0.289r = −0.342;
P = −0.452r = 0.218;
P = 0.487r = 0.180;
P = 0.699r = −0.162;
P = 0.728r = −0.414;
P = 0.355r = 0.198;
P = 0.670r = 0.440;
P = 0.323IL-2 (pg/mL) r = −0.750;
P = 0.052r = −0.750;
P = 0.052r = 0.180;
P = 0.699r = 0.001;
P = 0.999r = −0.286;
P = 0.535r = −0.571;
P = 0.180r = −0.107;
P = 0.819r = 0.582;
P = 0.170IL-6 (pg/mL) r = −0.714;
P = 0.071r = −0.393;
P = 0.383r = 0.342;
P = 0.452r = 0.979;
P = 0.702r = −0.286;
P = 0.535r = −0.321;
P = 0.482r = −0.214;
P = 0.645r = 0.200;
P = 0.667TNF-α2 (pg/mL) r = 0.464;
P = 0.294r = 0.429;
P = 0.337r = −0.505;
P = 0.248r = −0.357;
P = 0.432r = −0.750;
P = 0.052r = −0.643;
P = 0.119r = −0.214;
P = 0.645r = 0.618;
P = 0.139TGF-β1 (pg/mL) r = −0.214;
P = 0.645r = −0.179;
P = 0.702r = 0.198;
P = 0.670r = 0.429;
P = 0.337r = −0.321;
P = 0.482r = −0.321;
P = 0.482r = 0.286;
P = 0.535r = 0.327;
P = 0.474Note. ALT: Alanine aminotransferase, AST: aspartate aminotransferase, TBiL: Total bilirubin, DBiL: Direct bilirubin, GGT: glutamine transferase, ALP: alkaline phosphatase, TBA: Total bile acid, ALB: albumin, IFN-α2: interferon-alpha2, IFN-γ: interferon-gamma, IL-10: Interleukin-10, IL-17A: Interleukin-17A, IL-2: Interleukin-2, IL-6: Interleukin-6, TNF-α: tumor necrosis factor alpha, TGF-β1: transforming growth factor-beta1. Table 4. The correlation between clinical indicators and cytokines in anti infective drugs group
cytokines ALT (U/L) AST (U/L) TBiL (μmol/L) DBiL (μmol/L) GGT (U/L) ALP (U/L) TBA (μmol/L) ALB (g/L) IFN-α2 (pg/mL) r = 0.092;
P = 0.753r = 0.297;
P = 0.303r = 0.297;
P = 0.302r = 0.414;
P = 0.142r = −0.077;
P = 0.794r = 0.051;
P = 0.864r = 0.566;
P = 0.055r = −0.067;
P = 0.821IFN-γ (pg/mL) r = −0.004;
P = 0.988r = 0.106;
P = 0.719r = 0.252;
P = 0.384r = 0.363;
P = 0.202r = 0.079;
P = 0.788r = 0.264;
P = 0.361r = 0.435;
P = 0.120r = −0.154;
P = 0.600IL-10 (pg/mL) r = 0.301;
P = 0.295r = 0.424;
P = 0.131r = 0.436;
P = 0.119r = 0.541;
P = 0.056r = −0.103;
P = 0.725r = −0.015;
P = 0.958r = 0.641;
P = 0.054r = −0.202;
P = 0.488IL-17A (pg/mL) r = 0.051;
P = 0.864r = 0.112;
P = 0.703r = 0.163;
P = 0.578r = 0.191;
P = 0.512r = −0.029;
P = 0.923r = 0.029;
P = 0.923r = 0.330;
P = 0.249r = −0.269;
P = 0.353IL-2 (pg/mL) r = −0.110;
P = 0.708r = −0.121;
P = 0.680r = 0.242;
P = 0.404r = 0.209;
P = 0.473r = −0.046;
P = 0.875r = 0.119;
P = 0.686r = 0.222;
P = 0.446r = 0.133;
P = 0.649IL-6 (pg/mL) r = 0.084;
P = 0.775r = 0.190;
P = 0.515r = 0.425;
P = 0.130r = 0.449;
P = 0.107r = −0.113;
P = 0.701r = 0.080;
P = 0.787r = 0.390;
P = 0.168r = −0.345;
P = 0.227TNF-α2 (pg/mL) r = 0.211;
P = 0.469r = 0.222;
P = 0.446r = 0.299;
P = 0.299r = 0.352;
P = 0.217r = −0.182;
P = 0.533r = −0.270;
P = 0.350r = 0.355;
P = 0.242r = −0.171;
P = 0.559TGF-β1 (pg/mL) r = 0.272;
P = 0.347r = 0.286;
P = 0.322r = −0.226;
P = 0.438r = −0.058;
P = 0.843r = 0.224;
P = 0.441r = −0.211;
P = 0.469r = 0.053;
P = 0.857r = 0.071;
P = 0.809Note. ALT: Alanine aminotransferase, AST: aspartate aminotransferase, TBiL: Total bilirubin, DBiL: Direct bilirubin, GGT: glutamine transferase, ALP: alkaline phosphatase, TBA: Total bile acid, ALB: albumin, IFN-α2: interferon-alpha2, IFN-γ: interferon-gamma, IL-10: Interleukin-10, IL-17A: Interleukin-17A, IL-2: Interleukin-2, IL-6: Interleukin-6, TNF-α: tumor necrosis factor alpha, TGF-β1: transforming growth factor-beta1. Table 5. The correlation between clinical indicators and cytokines in other drugs group
Association of Cytokines with Clinical Indicators in Patients with Drug-Induced Liver Injury
doi: 10.3967/bes2024.054
- Received Date: 2023-11-08
- Accepted Date: 2024-03-05
-
Key words:
- Drug-induced liver injury /
- Cytokines /
- Non-steroidal anti-inflammatory drugs /
- Inflammation
Abstract:
All authors declare that there is no potential commercial and financial interest in this research.
&These authors contributed equally to this work.
Citation: | CAO Wei Hua, JIANG Ting Ting, SHEN Ge, DENG Wen, WANG Shi Yu, ZHANG Zi Yu, LI Xin Xin, LU Yao, ZHANG Lu, LIU Ru Yu, CHANG Min, WU Shu Ling, GAO Yuan Jiao, HAO Hong Xiao, CHEN Xiao Xue, HU Lei Ping, XU Meng Jiao, YI Wei, XIE Yao, LI Ming Hui. Association of Cytokines with Clinical Indicators in Patients with Drug-Induced Liver Injury[J]. Biomedical and Environmental Sciences, 2024, 37(5): 494-502. doi: 10.3967/bes2024.054 |